MedPeer Publisher

Sequential boost versus simultaneous integrated boost after breast radiotherapy: real-world practice, data completeness and exploratory outcomes in a single-centre cohort of 572 patients

Authors

Salma Ichou, Karima Nouni, Amine Lachgar, Hanan ElKacemi, Tayeb Kebdani, Khalid Hassouni

Journal Information

Journal: Medpeer Publisher

ISSN: 3066-2737

Volume: 3

Issue: 11

Date of Publication: 2026/11/15

DOI: 10.70780/medpeer.000QGYD

Abstract

Background. After breast-conserving surgery, the tumour-bed boost can be delivered sequentially or as a simultaneous integrated boost (SIB). Randomised trials support SIB, but real-world data from centres with limited linear accelerator capacity are scarce, and routine databases may not capture the outcomes needed for comparison. We described the use of both techniques in a reference centre, assessed the completeness of routinely recorded data, and explored acute toxicity and overall treatment time.
Methods. Retrospective single-centre study of a radiotherapy department database (2020–2023), reported according to STROBE. Patients with a recorded boost technique were included. Institutional schedules were 42 Gy in 15 fractions followed by a sequential boost of 11.2 Gy in 4 fractions, or 40.05 Gy in 15 fractions with a SIB of 48 Gy in 15 fractions. Outcomes were reported acute toxicity, CTCAE radiodermatitis grade and overall treatment time; completeness was assessed for each variable and group. Biologically equivalent doses (EQD2) of both schedules were calculated. The analysis was descriptive.
Results. Of 572 patients, 501 (87.6%) received a sequential boost and 71 (12.4%) a SIB. Reported acute toxicity was available for more than 97% of patients in both groups, and was reported in 13.5% (sequential) versus 1.4% (SIB) of them, but radiodermatitis grade was recorded for only 16.0% and 1.4% of patients, and overall treatment time for 9.8% and 81.7%, respectively. Median recorded overall treatment time was 21 days in both groups, below the minimum expected for the sequential schedule (25 days), indicating incomplete recording of end dates. The doses recorded for SIB patients (42 Gy to the breast, boost of 11.2 Gy) were those of the sequential schedule, suggesting misclassification of the technique, and 55% of patients had a mastectomy. On the protocol schedules, the sequential schedule had a higher EQD2 to both the whole breast and the tumour bed.
Conclusion. Sequential boost dominated practice, and routinely recorded data did not allow a valid comparison of toxicity or treatment duration between techniques. We propose a minimum dataset for prospective recording before comparative conclusions can be drawn.

Keywords

breast cancer; radiotherapy; tumour-bed boost; simultaneous integrated boost; radiodermatitis; overall treatment time; data quality; real-world data

Download PDF